ATE507293T1 - Zum gen-silencing geeignete konservierte hbv- und hcv-sequenzen - Google Patents
Zum gen-silencing geeignete konservierte hbv- und hcv-sequenzenInfo
- Publication number
- ATE507293T1 ATE507293T1 AT05854816T AT05854816T ATE507293T1 AT E507293 T1 ATE507293 T1 AT E507293T1 AT 05854816 T AT05854816 T AT 05854816T AT 05854816 T AT05854816 T AT 05854816T AT E507293 T1 ATE507293 T1 AT E507293T1
- Authority
- AT
- Austria
- Prior art keywords
- gene silencing
- sequences suitable
- hcv sequences
- hbv
- conserved hbv
- Prior art date
Links
- 230000030279 gene silencing Effects 0.000 title 1
- 238000012226 gene silencing method Methods 0.000 title 1
- 108091035707 Consensus sequence Proteins 0.000 abstract 1
- 241000711549 Hepacivirus C Species 0.000 abstract 1
- 241000700721 Hepatitis B virus Species 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Communicable Diseases (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Silicon Polymers (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63829404P | 2004-12-22 | 2004-12-22 | |
| PCT/US2005/046162 WO2006069064A2 (en) | 2004-12-22 | 2005-12-20 | Conserved hbv and hcv sequences useful for gene silencing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE507293T1 true ATE507293T1 (de) | 2011-05-15 |
Family
ID=36602266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05854816T ATE507293T1 (de) | 2004-12-22 | 2005-12-20 | Zum gen-silencing geeignete konservierte hbv- und hcv-sequenzen |
Country Status (7)
| Country | Link |
|---|---|
| EP (2) | EP1833967B1 (enExample) |
| JP (3) | JP2008525029A (enExample) |
| AT (1) | ATE507293T1 (enExample) |
| AU (1) | AU2005319306B9 (enExample) |
| CA (1) | CA2592099A1 (enExample) |
| DE (1) | DE602005027747D1 (enExample) |
| WO (1) | WO2006069064A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8575327B2 (en) * | 2003-06-12 | 2013-11-05 | Alnylam Pharmaceuticals, Inc. | Conserved HBV and HCV sequences useful for gene silencing |
| ES2362670T3 (es) * | 2004-09-24 | 2011-07-11 | Alnylam Pharmaceuticals, Inc | Orientación a intermedios de replicación de hebra no codificante de virus monocatenarios por arni. |
| EP3587574B1 (en) | 2010-08-17 | 2022-03-16 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina) |
| JP6042871B2 (ja) | 2011-04-21 | 2016-12-14 | アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | Ｂ型肝炎ウイルス（ｈｂｖ）発現の調節 |
| WO2013119793A1 (en) * | 2012-02-07 | 2013-08-15 | University Of Kansas | Chemiluminescent nanoparticles and uses thereof |
| WO2013159109A1 (en) * | 2012-04-20 | 2013-10-24 | Isis Pharmaceuticals, Inc. | Modulation of hepatitis b virus (hbv) expression |
| PT3363902T (pt) * | 2012-12-06 | 2019-12-19 | Sigma Aldrich Co Llc | Modificação e regulação de genoma baseadas em crispr |
| LT3074517T (lt) * | 2013-11-28 | 2021-11-25 | Bavarian Nordic A/S | Kompozicijos ir būdai, skirti sukelti padidintą imuninį atsaką, naudojant raupų viruso vektorius |
| JOP20200092A1 (ar) | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها |
| KR20170141257A (ko) * | 2015-05-06 | 2017-12-22 | 베니텍 바이오파마 리미티드 | B형 간염 바이러스 (hbv) 감염의 치료를 위한 시약 및 이의 용도 |
| US11535851B2 (en) | 2016-05-05 | 2022-12-27 | Benitec IP Holdings Inc. | Reagents for treatment of hepatitis B virus (HBV) infection and use thereof |
| CN110234763A (zh) * | 2016-11-11 | 2019-09-13 | 詹森生物制药有限公司 | 针对hbv cccdna的寡核苷酸靶向策略 |
| AU2017368050A1 (en) | 2016-11-29 | 2019-06-20 | Puretech Lyt, Inc. | Exosomes for delivery of therapeutic agents |
| US11324820B2 (en) | 2017-04-18 | 2022-05-10 | Alnylam Pharmaceuticals, Inc. | Methods for the treatment of subjects having a hepatitis b virus (HBV) infection |
| UA127745C2 (uk) | 2018-08-13 | 2023-12-20 | Альнілам Фармасьютікалз, Інк. | КОМПОЗИЦІЇ, ЩО МІСТЯТЬ ЗАСІБ НА ОСНОВІ dsRNA ВІРУСУ ГЕПАТИТУ В (HBV), ТА СПОСОБИ ЇХ ВИКОРИСТАННЯ |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5643771A (en) | 1980-05-19 | 1997-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | Non-reverting live bacterial vaccines |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| EP0400047B1 (en) | 1988-02-05 | 1997-04-23 | Whitehead Institute For Biomedical Research | Modified hepatocytes and uses therefor |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| WO1995027788A1 (en) * | 1994-04-11 | 1995-10-19 | Dainabot Co., Ltd. | Polypeptide derived from variant hepatitis b virus, gene encoding the same, and related dna |
| US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
| US5877159A (en) | 1995-05-03 | 1999-03-02 | University Of Maryland At Baltimore | Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same |
| US5932241A (en) | 1995-06-07 | 1999-08-03 | Valentis, Incorporated | Cationic lipid DNA complexes for gene targeting |
| US5874565A (en) | 1995-08-29 | 1999-02-23 | Washington University | Nucleic acids comprising a highly conserved novel 3 terminal sequence element of the hepatitis C virus |
| US5824538A (en) | 1995-09-06 | 1998-10-20 | The United States Of America As Represented By The Secretary Of The Army | Shigella vector for delivering DNA to a mammalian cell |
| US5843770A (en) * | 1996-03-11 | 1998-12-01 | The Immune Response Corporation | Antisense constructs directed against viral post-transcriptional regulatory sequences |
| US6217900B1 (en) | 1997-04-30 | 2001-04-17 | American Home Products Corporation | Vesicular complexes and methods of making and using the same |
| CA2306733A1 (en) | 1997-10-28 | 1999-05-06 | American Home Products Corporation | Compositions and methods for delivery of genetic material |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| JP2002506801A (ja) | 1998-03-16 | 2002-03-05 | ザ、プロクター、エンド、ギャンブル、カンパニー | 哺乳類の皮膚のセルライトを軽減する方法 |
| WO2000063364A2 (en) | 1999-04-21 | 2000-10-26 | American Home Products Corporation | Methods and compositions for inhibiting the function of polynucleotide sequences |
| WO2001038498A2 (en) * | 1999-11-24 | 2001-05-31 | Pharmasset, Ltd. | A new genotype of hepatitis b virus |
| HK1048492A1 (zh) * | 1999-12-03 | 2003-04-04 | Innogenetics N.V. | 新的hbv序列 |
| EP1229134A3 (en) | 2001-01-31 | 2004-01-28 | Nucleonics, Inc | Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell |
| AU2002250254A1 (en) * | 2001-03-09 | 2002-09-24 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| DE10163098B4 (de) * | 2001-10-12 | 2005-06-02 | Alnylam Europe Ag | Verfahren zur Hemmung der Replikation von Viren |
| AU2003207708A1 (en) * | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
| AU2003265935A1 (en) | 2002-05-03 | 2003-11-17 | Harman International Industries, Incorporated | Sound detection and localization system |
| EP1540004A4 (en) | 2002-07-31 | 2007-10-03 | Nucleonics Inc | DOUBLE-STRING RNA STRUCTURES AND CONSTRUCTS AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| US7303906B2 (en) | 2002-09-06 | 2007-12-04 | Wisconsin Alumni Research Foundation | Competent bacteria |
| AU2003284323A1 (en) | 2002-10-18 | 2004-05-04 | Alnylam Pharmaceuticals Inc | Double-stranded rna structures and constructs, and methods for generating and using the same |
| DK2284266T3 (da) * | 2002-11-14 | 2014-01-13 | Thermo Fisher Scient Biosciences Inc | sIRNA-MOLEKYLE MOD TP53 |
| CN101914532A (zh) * | 2002-11-22 | 2010-12-15 | 生物智囊团株式会社 | Rna干扰的目标碱基序列的搜索方法 |
| US6673661B1 (en) | 2002-12-20 | 2004-01-06 | Taiwan Semiconductor Manufacturing Co., Ltd. | Self-aligned method for forming dual gate thin film transistor (TFT) device |
| WO2004063375A1 (en) * | 2003-01-15 | 2004-07-29 | Hans Prydz | OPTIMIZING siRNA BY RNAi ANTISENSE |
| EP2071030A3 (en) * | 2003-01-24 | 2009-07-22 | Tokyo Metropolitan Organization for Medical Research | Oligoribonucleotide or peptide nucleic acid which inhibits action of hepatitis C virus |
| EP1597351B1 (en) | 2003-02-27 | 2012-04-18 | Alnylam Pharmaceuticals Inc. | METHODS AND CONSTRUCTS FOR EVALUATION OF RNAi TARGETS AND EFFECTOR MOLECULES |
| CN1257284C (zh) * | 2003-03-05 | 2006-05-24 | 北京博奥生物芯片有限责任公司 | 一种体外阻断乙肝病毒表达的方法 |
| BRPI0411219A (pt) * | 2003-06-12 | 2006-07-18 | Nucleonics Inc | seqüências de hbv e hcv conservadas úteis para silenciamento de gene |
| US20050130184A1 (en) | 2003-07-18 | 2005-06-16 | University Of Massachusetts | Enhanced promoters for synthesis of small hairpin RNA |
| US20050130919A1 (en) | 2003-07-18 | 2005-06-16 | University Of Massachusetts | Regulatable promoters for synthesis of small hairpin RNA |
| WO2006033756A2 (en) * | 2004-08-23 | 2006-03-30 | Nucleonics, Inc. | Multiple rna polymerase iii promoter expression constructs |
| JP5671371B2 (ja) * | 2011-03-01 | 2015-02-18 | 株式会社山本鉄工所 | 連続プレス装置 |
| JP2015086965A (ja) | 2013-10-31 | 2015-05-07 | 株式会社エクセディ | フライホイール組立体 |
-
2005
- 2005-12-20 WO PCT/US2005/046162 patent/WO2006069064A2/en not_active Ceased
- 2005-12-20 JP JP2007548393A patent/JP2008525029A/ja active Pending
- 2005-12-20 DE DE602005027747T patent/DE602005027747D1/de not_active Expired - Lifetime
- 2005-12-20 AT AT05854816T patent/ATE507293T1/de not_active IP Right Cessation
- 2005-12-20 AU AU2005319306A patent/AU2005319306B9/en not_active Ceased
- 2005-12-20 EP EP05854816A patent/EP1833967B1/en not_active Expired - Lifetime
- 2005-12-20 CA CA002592099A patent/CA2592099A1/en not_active Abandoned
- 2005-12-20 EP EP10010655.8A patent/EP2316942B1/en not_active Expired - Lifetime
-
2012
- 2012-08-13 JP JP2012179638A patent/JP2012223202A/ja active Pending
-
2014
- 2014-09-03 JP JP2014179056A patent/JP5934310B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1833967A2 (en) | 2007-09-19 |
| AU2005319306B9 (en) | 2012-04-05 |
| WO2006069064A2 (en) | 2006-06-29 |
| JP2008525029A (ja) | 2008-07-17 |
| AU2005319306B2 (en) | 2012-01-12 |
| EP1833967B1 (en) | 2011-04-27 |
| CA2592099A1 (en) | 2006-06-29 |
| AU2005319306A1 (en) | 2006-06-29 |
| JP5934310B2 (ja) | 2016-06-15 |
| EP2316942B1 (en) | 2021-04-21 |
| EP2316942A1 (en) | 2011-05-04 |
| DE602005027747D1 (de) | 2011-06-09 |
| JP2012223202A (ja) | 2012-11-15 |
| WO2006069064A3 (en) | 2007-10-25 |
| JP2015003913A (ja) | 2015-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005014806A3 (en) | Conserved hbv and hcv sequences useful for gene silencing | |
| ATE507293T1 (de) | Zum gen-silencing geeignete konservierte hbv- und hcv-sequenzen | |
| CY1119273T1 (el) | Προπανοϊκου (s)-ισοπροπυλιου | |
| MY176918A (en) | N- [ (2 ' r) -2' -deoxy-2' -fluoro-2' -methyl-p-phenyl-5' -uridylyl] - l-alanine 1-methylethyl ester and process for its production | |
| EP2609923A3 (en) | Nucleoside Phosphoramidates | |
| DK1747023T3 (da) | Fremgangsmåder og sammensætninger til formindskelse af HCV-virusgenommængder i en målcelle | |
| DK1554301T3 (da) | Dengue-vaccine med en fælles udeladelse af 30 nukleotider i Dengue-typerne 1's og 2's3'UTR | |
| EA200700243A1 (ru) | Способы лечения гепатита с | |
| MX2011007693A (es) | Metodos para amplificar acidos nucleicos del virus de hepatitis c. | |
| JP2012136542A5 (enExample) | ||
| TW200728317A (en) | Macrocylic inhibitors of hepatitis C virus | |
| WO2007127801A3 (en) | Hepatitis c virus infection biomarkers | |
| WO2010047830A3 (en) | Agents for hcv treatment | |
| WO2009091388A3 (en) | Triazines and related compounds having antiviral activity, compositions and methods thereof | |
| MA32634B1 (fr) | Polytherapie destinee a traiter une infection par le vhc | |
| WO2010055164A3 (en) | Isoquinolone derivatives as inhibitors of plavivirus replication | |
| AU2021288648A8 (en) | Conjugate of double-stranded siRNA analogue | |
| EA200401362A1 (ru) | Антивирусная терапия, основанная на противодействии рнк | |
| EA200701695A1 (ru) | Рнк вирусы с ослабленной способностью к репликации в качестве вакцин | |
| PH12022553394A1 (en) | Conjugate of double-stranded sirna analogue | |
| EP4410970A3 (en) | Efficient cell culture system for hepatitis c virus genotype 6a | |
| EA200802101A1 (ru) | Конструкции-"шпильки" р15 и применение | |
| Zhao et al. | The 2016 Lasker-DeBakey Clinical Medical Research Award: Innovative hepatitis C virus (HCV) replicons leading to drug development for hepatitis C cure | |
| TW201129362A (en) | Heterocyclic antiviral compounds | |
| Khanna et al. | Genome-wide prediction and analysis of siRNA as potential antiviral agent against Hepatitis-C virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |